#ThinkSabio Latest News
Most patients on Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease achieved sustained clinical remission and endoscopic response at two years
Most patients on Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease achieved sustained clinical remission and endoscopic response at two years